Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

pdf

Aurobindo Pharma Ltd.

03 Oct 2026

1693.00

2.92%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.

pdf

Aurobindo Pharma Ltd.

02 Oct 2026

1693.00

2.92%

Company Update

Aurobindo Pharma Ltd - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & …

BSE India

Intimation of completion of acquisition.

pdf

Aurobindo Pharma Ltd.

02 Oct 2026

1693.00

2.92%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Intimation of acquisition of a step down subsidiary in USA.

pdf

Aurobindo Pharma Ltd.

01 Oct 2026

1693.00

2.92%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.

pdf

Aurobindo Pharma Ltd.

30 Sep 2026

1693.00

2.92%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.

pdf